Skip to main content
Top
Published in: International Cancer Conference Journal 1/2024

31-08-2023 | Dermatomyositis | Case Report - Complication

Two cases of dermatomyositis associated with neuroendocrine tumors

Authors: Uria Shani, Noy Lavine, Esther Houri-Levi, Abdalla Watad, Howard Amital

Published in: International Cancer Conference Journal | Issue 1/2024

Login to get access

Abstract

Dermatomyositis is an idiopathic inflammatory myopathy with cutaneous manifestations, which is associated with several types of malignancies, yet it has been rarely linked to neuroendocrine tumors (NETs). Here we report two cases of dermatomyositis associated with NETs of differing primary sites. Case 1: A 46-year-old female presented with a facial rash and proximal muscle weakness of both extremities. Investigations revealed elevated creatine kinase (CK) and positive anti-transcriptional intermediary factor 1-γ antibody (TIF1γ). The patient had been diagnosed with dermatomyositis and underwent a total body CT scan, which revealed prominent mediastinal lymphadenopathy, which a subsequent biopsy determined to be neuroendocrine carcinoma of small cell type. Treatment with high-dose corticosteroids was initiated, in addition to chemotherapy-based oncological management. Case 2: A 54-year-old female presented with a facial rash, progressive dyspnea, and general malaise. Laboratory investigations revealed positive anti-melanoma differentiation-associated gene-5 (MDA5) and positive anti-Ro antibody, with a normal level of creatine kinase (CK). A chest CT scan revealed multiple ground-glass opacities. Despite treatment with high-dose intravenous methylprednisolone, IVIG and an infusion of the anti-IL-6 sarilumab [Kevzara], the patient rapidly deteriorated and was intubated. Within days, the patient developed bowel ischemia and underwent a laparotomy which was then complicated by an invasive infection. This resulted in patient’s death. Pathology results from colonic tissue demonstrated an appendiceal neuroendocrine tumor. These cases demonstrate the heterogeneity and complexity of dermatomyositis in association with neuroendocrine tumors.
Literature
1.
go back to reference Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828CrossRefPubMed Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828CrossRefPubMed
2.
go back to reference Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353CrossRefPubMed Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353CrossRefPubMed
3.
go back to reference Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921CrossRefPubMed Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921CrossRefPubMed
8.
9.
go back to reference Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136CrossRefPubMed Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136CrossRefPubMed
11.
go back to reference Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002CrossRef Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002CrossRef
12.
go back to reference La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538CrossRefPubMed La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538CrossRefPubMed
13.
go back to reference Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158CrossRef Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158CrossRef
14.
go back to reference Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221 Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221
16.
go back to reference Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2 Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2
17.
go back to reference Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7 Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7
18.
go back to reference Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383 Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383
28.
go back to reference Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897PubMed Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897PubMed
30.
33.
go back to reference dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1 dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1
Metadata
Title
Two cases of dermatomyositis associated with neuroendocrine tumors
Authors
Uria Shani
Noy Lavine
Esther Houri-Levi
Abdalla Watad
Howard Amital
Publication date
31-08-2023
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal / Issue 1/2024
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-023-00629-3

Other articles of this Issue 1/2024

International Cancer Conference Journal 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine